Table 2.

SAEs and AEsLeading to Discontinuation in Patients Stratified by Baseline Use/Nonuse of Cardiovascular Medications

AE, n/N (%)	With use of cardiovascular medication		Without use of cardiovascular medication
	Dapagliflozin	Placebo	Dapagliflozin	Placebo
ACEi use
Any AE leading to discontinuation of the study drug	39/673 (5.8)	30/678 (4.4)	79/1476 (5.4)	93/1471 (6.3)
Any SAE*	211/673 (31.4)	229/678 (33.8)	422/1476 (28.6)	500/1471 (34.0)
ARB use
Any AE leading to discontinuation of the study drug	76/1441 (5.3)	86/1426 (6.0)	42/708 (5.9)	37/723 (5.1)
Any SAE*	406/1441 (28.2)	482/1426 (33.8)	227/708 (32.1)	247/723 (34.2)
Calcium channel blocker use
Any AE leading to discontinuation of the study drug	56/1073 (5.2)	67/1108 (6.0)	62/1076 (5.8)	56/1041 (5.4)
Any SAE*	311/1073 (29.0)	412/1108 (37.2)	322/1076 (29.9)	317/1041 (30.5)
β‐blocker use
Any AE leading to discontinuation of the study drug	44/843 (5.2)	46/833 (5.5)	74/1306 (5.7)	77/1316 (5.9)
Any SAE*	292/843 (34.6)	345/833 (41.4)	341/1306 (26.1)	384/1316 (29.2)
Diuretic use
Any AE leading to discontinuation of the study drug	56/927 (6.0)	57/953 (6.0)	62/1222 (5.1)	66/1196 (5.5)
Any SAE*	330/927 (35.6)	391/953 (41.0)	303/1222 (24.8)	338/1196 (28.3)
Antithrombotic agent use
Any AE leading to discontinuation of the study drug	52/1022 (5.1)	62/1018 (6.1)	66/1127 (5.9)	61/1131 (5.4)
Any SAE*	368/1022 (36.0)	414/1018 (40.7)	265/1127 (23.5)	315/1131 (27.9)
Lipid‐lowering agent use
Any AE leading to discontinuation of the study drug	18/320 (5.6)	25/325 (7.7)	100/1829 (5.5)	98/1824 (5.4)
Any SAE*	99/320 (30.9)	120/325 (36.9)	534/1829 (29.2)	609/1824 (33.4)

ACEi indicates angiotensin‐converting enzyme inhibitor; AE, adverse event; ARB, angiotensin receptor blockers; and SAE, serious adverse event.

^*Includes death.